Delivery Order SPE2DB24D3015-SPE2DB25FGAGW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with a ceiling value of $1,314.73 under a firm fixed-price arrangement. The contract was competitively awarded without set-aside provisions and is due for completion by September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector medication with a contract ceiling value of $2,476.04. This firm fixed-price delivery order, which extends through August 29, 2025, represents a pediatric or adult testosterone replacement therapy product to support federal medical supply requirements. The contract was competitively awarded without a set-aside designation and will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,375.49. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. Performance will be executed from the company's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,544.96 to supply Xyosted 50 mg/0.5 mL auto-injector units. The contract, awarded on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy auto-injector prescribed for hormone...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units valued at $1,094.38 with a firm fixed price structure. This non-set-aside contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAGWDelivery Order
This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Xyosted, a testosterone replacement therapy auto-injector, represents one of the specialty medications within AmerisourceBergen's portfolio of deliveries supporting Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/28/25 |